Singapore O&G still growing strong

Singapore O&G still growing strong

Samantha Chiew
15/05/18, 10:48 am

SINGAPORE (May 15): Phillip Capital is maintaining its “accumulate” recommendation on Singapore O&G (SOG) with a target price of 42 cents.

The group on Monday announced that its 1Q18 earnings have increased by 23.7% to $2.5 million, compared to $2.0 million in 1Q17.

Revenue was 17.3% higher at $8.2 million from $7.0 million last year, on the back of higher contribution from its Obstetrics & Gynaecology (O&G), Cancer-related, and Dermatology segments, as well as maiden contribution from its new Paediatrics segment.

See: Singapore O&G posts 23.7% rise in 1Q earnings to $2.5 mil on higher revenue

In a Tuesday report, analyst Soh Li Sin says, “We expect its Cancer-related segment to support Group’s FY18e profitability amidst persistent headwinds – sluggish birth rate; and structural slowdown in medical tourism.”

In addition, the group is also introducing new income streams, including collaborating with SATA CommHealth, which will commence in end-May, as well as tapping into an unserved niche market for High Intensity Focused Ultrasound (HIFU) treatment.

SOG will provide on-site medical services to SATA CommHealth with 50% profit sharing for an initial term of 12 months.

“While we do not expect a significant revenue generated from this collaboration, it allows the Group to expand its potential patient pool in the heartland areas,” says Soh.

Meanwhile, the HIFU treatment is a non-surgical procedure to treat uterine fibroid, using focused ultrasound energy, as well as liver tumour. Farrer Park Hospital is expected to bring in this machine in the coming months.

The group believes that this new treatment could attract foreign patients from the region, as it is currently only available in China, South Korea and Myanmar in Asia.

Moreover, the group has also been actively hiring new medical practitioners to expand its four growth pillars. It targets to hire two to three new specialists to its O&G, Dermatology and/or Paediatrics segments by FY18.

“We are cognisant of the margin pressures arising from the latent period of the new doctors,” says Soh.

The analyst also likes SOG for its consistency in gaining traction in the O&G market.

As at 10.45am, shares in SOG are trading flat at 38 cents or 4.0 times FY18 book with a dividend yield of 4.1%.

Jokowi declared winner a month after Indonesia presidential vote

(May 21): Indonesian President Joko Widodo won last month’s bitterly contested election by a double-digit margin, official results showed Tuesday, putting the former furniture exporter in charge of the world’s largest Muslim-majority nation for another five years. Widodo, known as Jokowi, won 55.5% of the national vote, compared to his challenger Prabowo Subianto’s 44.5%, the General Elections Commission said in Jakarta early on Tuesday. Jokowi’s margin of victory at 11% was almost double the lead he secured in 2014 against the same opponent, commission’s data showed. The tally al....

Sembcorp Industries' near-term outlook hinges on sustained India uptrend, say analysts

SINGAPORE (May 21): CGS-CIMB Research and DBS Vickers Securities are maintaining their “add” and “buy” calls on Sembcorp Industries (SCI) with target prices of $3.41 and $3.90, respectively. This comes after the group last week posted 21% higher 1Q earnings of $77 million on higher contributions from its energy segment, which was mainly driven by improved performance from India and the recognition of peak winter availability payments for UK Power Reserve. In a May 15 report, CGS-CIMB analyst Lim Siew Khee says she considers SCI cheap at $2.54, which is 0.6 times FY19 price-to-boo....

China warns about 'unwavering resolve' to fight 'US bullying'

BRUSSELS (May 21): China could retaliate against the US after President Donald Trump blacklisted Huawei Technologies Co., the Chinese ambassador to the European Union said. Trump upped the ante in his trade dispute with China last week, announcing moves to curb Huawei’s business that are starting to have ramifications for other companies around the world. "This is wrong behavior, so there will be a necessary response," Zhang Ming, China’s envoy to the EU, said in an interview in Brussels on Monday. "Chinese companies’ legitimate rights and interests are being undermined, so the Chi....